Gain Therapeutics reports positive exploratory endpoint from Phase 1b study of GT-02287 in Parkinson's Disease

Gain Therapeutics, Inc.

GT-02287 reduced elevated GluSph in CSF to near-normal levels after 90 days in Phase 1b study.
19 of 21 enrolled participants completed 90-day dosing; 15 (79%) chose to continue in 9-month extension ending Sept 2026.
Drug well-tolerated; data monitoring committee recommended study continue with no changes.
Company has capital to fund operations through end of Phase 1b extension and year-end 2026.
Phase 1 healthy volunteer study showed favorable safety, target engagement with increased GCase activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.